Filtered By:
Condition: Heart Disease
Nutrition: Vitamins

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 411 results found since Jan 2013.

Evaluation of stroke incidence with duty ‐cycled multielectrode‐phased radiofrequency ablation of persistent atrial fibrillation results of the VICTORY AF Study
ConclusionsVICTORY AF demonstrated a 1.6% incidence of stroke in PersAF undergoing ablation with a phased RF system which did not meet statistical confidence due to poor enrollment. The secondary outcomes suggest comparable efficacy to phased RF in the tailored treatment of permanent AF trial. Rigorous clinical evaluation of the stroke risk of new AF ablation technologies as well as restriction to Vitamin K antagonist anticoagulation appears to be unachievable goals in a clinical multicenter IDE trial of AF ablation in the current era.
Source: Journal of Cardiovascular Electrophysiology - April 23, 2020 Category: Cardiology Authors: John Hummel, Atul Verma, Hugh Calkins, Lee H. Schwamm, Daryl Gress, Darryl Wells, Joseph Souza, Robert B. Hokanson, Lauren Hemingway, Kurt Stromberg, Robert Hoyt, Andrew Wickliffe, David DeLurgio, Lucas Boersma Tags: ORIGINAL ARTICLE Source Type: research

Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs
Publication date: Available online 14 March 2015 Source:The Lancet Author(s): Freek W A Verheugt , Christopher B Granger In patients with non-valvular atrial fibrillation, oral anticoagulation with vitamin K antagonists reduces the risk of stroke by more than 60%. But vitamin K antagonists have limitations, including causing serious bleeding such as intracranial haemorrhage and the need for anticoagulation monitoring. In part related to these limitations, they are used in only about half of patients who should be treated according to guideline recommendations. In the past decade, oral agents have been developed that dire...
Source: The Lancet - March 14, 2015 Category: Journals (General) Source Type: research

How To Lower Risk of Heart Disease and Stroke
Italy's Emma Morano will be celebrating her 117th birthday at the end of this month. She's the oldest living person in the world. And when she was asked what her secret to longevity was, she didn't miss a beat. Her answer? She eats two or three eggs every day.  I'm not at all surprised by Emma's long, healthy life. People thrived on eggs for millions of years. The Myth of Eggs and Cholesterol That is, until the 1950s, when they came under attack because they're high in cholesterol. Around that time, cholesterol was blamed for causing heart disease. And we now know that's not true. Choleste...
Source: Al Sears, MD Natural Remedies - December 15, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants.
Abstract The last ten years have seen rapid strides in the evolution of nonvitamin K oral anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation (AF). For the preparation of this consensus, a comprehensive literature search was performed and data on available trials, subpopulation analyses, and case reports were analyzed. This Indian consensus document intends to provide guidance on selecting the right NOAC for the right patients by formulating expert opinions based on the available trials and Asian/Indian subpopulation analyses of these trials. A section has been dedicated to the curren...
Source: Indian Heart J - December 1, 2015 Category: Cardiology Authors: Dalal J, Bhave A, Oomman A, Vora A, Saxena A, Kahali D, Poncha F, Gambhir DS, Chaudhuri JR, Sinha N, Ray S, Iyengar SS, Banerjee S, Kaul U, SPAF Academy India experts Tags: Indian Heart J Source Type: research

Oral anticoagulation for stroke prevention amongst atrial fibrillation patients with valvular heart disease: an update
This article will review current knowledge, areas of uncertainty and controversy, and ongoing research on oral anticoagulation for stroke prevention amongst patients with valvular heart disease. Recent findings: The rates of stroke, systemic embolism, and major bleeding were similar for patients with and without significant native valvular disease when treated with direct oral anticoagulants (DOACs) or vitamin K antagonists. There are very limited prospective data on the safety and efficacy of DOAC use for patients with bioprosthetic valves or rheumatic mitral stenosis. Summary: Atrial fibrillation patients with concomit...
Source: Current Opinion in Cardiology - February 10, 2017 Category: Cardiology Tags: VALVULAR HEART DISEASE: Edited by Subodh Verma Source Type: research

Calcium supplements associated with increased risk of cardiovascular death in men but not women
Commentary on: Xiao Q, Murphy RA, Houston DK, et al.. Dietary and supplemental calcium intake and cardiovascular disease mortality: the National Institutes of Health-AARP diet and health study. JAMA Intern Med 2013;173:639–46 Implications for practice and research Calcium supplements increase cardiovascular risk. The role of calcium supplements in the management of osteoporosis should be reconsidered. Context In 2008, a randomised controlled trial (RCT) suggested that calcium supplements might increase the risk of cardiovascular events.1 Subsequent meta-analyses of RCTs examining calcium monotherapy and calcium and v...
Source: Evidence-Based Nursing - June 17, 2014 Category: Nursing Authors: Bolland, M. J., Grey, A. Tags: Primary health care, Drugs: cardiovascular system, Stroke, Diet, Ischaemic heart disease, Osteoporosis Source Type: research

The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants
Publication date: December 2015 Source:Indian Heart Journal, Volume 67, Supplement 2 Author(s): Jamshed Dalal, Abhay Bhave, Abraham Oomman, Amit Vora, Anil Saxena, Dhiman Kahali, Fali Poncha, D.S. Gambhir, Jaydip Ray Chaudhuri, Nakul Sinha, Saumitra Ray, S.S. Iyengar, Suvro Banerjee, Upendra Kaul The last ten years have seen rapid strides in the evolution of nonvitamin K oral anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation (AF). For the preparation of this consensus, a comprehensive literature search was performed and data on available trials, subpopulation analyses, and ca...
Source: Indian Heart Journal - December 11, 2015 Category: Cardiology Source Type: research

Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease.
Authors: Ahmad S, Wilt H Abstract There is a clinically staggering burden of disease stemming from cerebrovascular events, of which a majority are ischemic in nature and many are precipitated by atrial fibrillation (AF). AF can occur in isolation or in association with myocardial or structural heart disease. In the latter case, and when considering health at an international level, congenital and acquired valve-related diseases are frequent contributors to the current pandemic of AF and its clinical impact. Guidelines crafted by the American Heart Association, American College of Cardiology, European Society of Car...
Source: Open Cardiovascular Medicine Journal - June 29, 2016 Category: Cardiology Tags: Open Cardiovasc Med J Source Type: research

In people with atrial fibrillation receiving antithrombotics, short-term non-steroidal anti-inflammatory drug exposure increases risk of serious bleeding
Commentary on: Lamberts M, Lip GYH, Hansen ML, et al. Relation of non-steroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy Ann Intern Med 2014;161:690–8. Implications for practice and research Short courses of non-steroidal anti-inflammatory drugs (NSAIDs) should be used with caution in patients with atrial fibrillation (AF) already taking antithrombotic therapy for stroke prevention since there is an increased risk of serious bleeding and clot formation. Research needs to be carried out on whether combined NSAID and non-v...
Source: Evidence-Based Nursing - December 15, 2015 Category: Nursing Authors: Myat, A. Tags: GI bleeding, Adult nursing, Drugs: cardiovascular system, Pain (neurology), Stroke, Ischaemic heart disease, Pain (palliative care), Pain (anaesthesia), Drugs: musculoskeletal and joint diseases, Arrhythmias Source Type: research

Vitamin D and estradiol help guard against heart disease, stroke, and diabetes
(The North American Menopause Society (NAMS)) Vitamin D and estrogen have already shown well-documented results in improving bone health in women. A new study from China suggests that this same combination could help prevent metabolic syndrome, a constellation of conditions that increases the risk of heart disease, stroke, and diabetes in postmenopausal women. Results are published online today in Menopause, the journal of The North American Menopause Society (NAMS).
Source: EurekAlert! - Medicine and Health - June 12, 2019 Category: International Medicine & Public Health Source Type: news

Most vitamins, minerals won't prevent heart disease, stroke or cancer, panel warns
In a move that could upend the multi-billion-dollar U.S. vitamin industry, an authoritative panel of experts said most vitamins, minerals and multivitamin supplements won't prevent heart disease, stroke or cancer.
Source: Health News - UPI.com - June 21, 2022 Category: Consumer Health News Source Type: news

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Oversleeping: The Effects and Health Risks of Sleeping Too Much
This article originally appeared on the Amerisleep blog. Rosie Osmun is the Creative Content Manager at Amerisleep, a progressive memory foam mattress brand focused on eco-friendly sleep solutions. Rosie writes more posts on the Amerisleep blog about the science of sleep, eco-friendly living, leading a healthy lifestyle and more. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.
Source: Healthy Living - The Huffington Post - January 29, 2016 Category: Consumer Health News Source Type: news